Controversy exists regarding the early use of glycoprotein IIb/IIIa inhibitors (GPIs) in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). The Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial provides a unique opportunity to examine early vs. late or non-use of GPIs in a large STEMI cohort treated with PCI.
Introduction
Several randomized trials have shown that timely expert primary coronary angioplasty (PCI) is the best reperfusion strategy with respect to survival and reduction of combined clinical endpoints in the treatment of ST-segment elevation myocardial infarction (STEMI). 1 However, attempts to extend PCI to the majority of STEMI patients may be associated with delay to reperfusion, which in turn might negatively impact on clinical outcome. 2 -4 Meta-analyses of the adjunctive use of the glycoprotein IIb/IIIa receptor inhibitor (GPI) abciximab suggests that this strategy is associated with a reduced mortality in STEMI patients undergoing primary angioplasty. 5, 6 Early administration of GPIs seemed even more attractive, because faster recanalization of the infarct-related artery might attenuate the negative impact of any potential delay to PCI related to transfer and organization logistics on clinical outcome. 3, 7 This approach has been supported by a beneficial effect on surrogate markers from their use in different trials and registries 8 -20 and meta-analyses. 21 -23 However, these results were contradicted by the facilitated PCI in patients with ST-elevation myocardial infarction (FINESSE) trial, 24 which failed to show benefit of early pre-lab use of full-dose abciximab or the combination of full-dose abciximab plus half-dose reteplase on a combined ischaemic endpoint when compared with the in-lab use of full-dose abciximab. Moreover, bleeding complications were significantly increased with the early use of pharmacological reperfusion strategies. These unfavourable results influenced the new European guidelines for STEMI treatment, which declare that GPI pre-treatment of STEMI patients on transfer to PCI is not recommended. 25 The Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial was originally designed to prevent reperfusion injury by testing pexelizumab vs. placebo on top of optimal and guideline-related antithrombotic treatment strategies before and during PCI in patients with acute STEMI. 26 Pexelizumab was neutral on efficacy and side effects. Glycoprotein IIb/IIIa inhibitor use was encouraged and the majority of patients were so treated either early, i.e. prior to sheath insertion (pre-sheath) or late (peri-procedural) during catheterization (in-lab). The present study examined the association of pre-sheath, in-lab or non-use of GPIs with 90-day clinical outcomes in a large STEMI patient cohort treated with PCI.
Methods
This trial enrolled 5745 patients presenting from 296 hospitals in 17 countries from 13 July 2004 to 11 May 2006. Patients presenting within 6 h of symptom onset were randomly assigned to receive either placebo or pexelizumab. Patients received one of three commercially available GPIs (abciximab, eptifibatide, tirofiban) at the operator's discretion. Their use was strongly encouraged based on the existing guidelines but was subject to local discretionary practice. The primary endpoint of the trial was 90-day mortality and the composite of death, centrally adjudicated congestive heart failure (CHF), or cardiogenic shock at 90 days. Because no significant difference was observed in the primary endpoint between the treatment and placebo arms, both arms were pooled for the current analysis. We also analysed in-hospital severe and moderate bleeding complications (and the combination of) based on the Global Use of Strategies to Open Occluded Coronary Arteries classification 27 and in-hospital and 90-day stroke as the major safety endpoints.
Statistical analysis
Prior to the unblinding of the trial data, a statistical analysis plan was developed for the current study and followed herein. Continuous and discrete characteristics were presented as median (25th, 75th percentile) and percentages, respectively. Differences in these characteristics among recipients and non-recipients of GPI and among pre-sheath and in-lab recipients were assessed using (non-parametric) Mann-Whitney U or x 2 tests, as appropriate.
Given that patients were not randomized for GPI use, patients receiving this treatment may not be comparable to those not receiving GPI treatment. Because direct comparison of observed outcomes between the treatment groups is not appropriate, an inverse-probability-weighted method was applied in the current study. Briefly, this approach, rooted in propensity score-based methods, applies the inverse of the propensity score estimators to adjust for confounding. 28 The propensity scores were determined in a stepwise approach from logistic regression models. Factors influencing both the likelihood of GPI and the clinical outcome were included in these models (i.e. pre-sheath and no GPI: age, sex, BMI, systolic blood pressure, heart rate, hypertension, diabetes, prior stroke, prior CHF, prior MI, prior PCI, prior thienopyridine use, renal function, smoking status, Killip class, MI location, baseline ST-deviation, time from symptom onset to randomization, transfer to a PCI centre, geographic region; in-lab GPI: all prior plus LAD as the culprit artery, multivessel disease, pre-PCI TIMI flow grade). From these models, the predicted probabilities were used to construct the inverse probability weights and were then further 'stabilized' by replacing the numerator with the unadjusted probability of receiving GPI. The extent to which the models balance the treatment groups was assessed by stratifying the cohort by quintiles of predicted probability of treatment and comparing observed patient characteristics between the treatment groups within the quintiles. Cox regression models were then fitted for 90-day all-cause mortality and composite of death/CHF/shock with the stabilized weights to estimate the adjusted hazard ratios (HRs) and corresponding robust 95% confidence intervals (CIs). 29, 30 Statistical testing was conducted using two-sided alternatives with a type I error level of 0.05, using the SAS package (Version 9.1; Cary, NC, USA).
Results
Of the 5745 patients enrolled in APEX-AMI trial, 5707 (99.3%) underwent coronary angiography and had a documented date and time for the start of GPI bolus; thus, these patients comprised the current study population ( Figure 1 ). Overall, GPI was administered in 69.5% of patients with 1125 (28.3%) patients received GPI early (i.e. pre-sheath) and 2844 (72.7%) patients receiving GPI in-lab. Patients not receiving GPIs were more likely older, female, diabetic, and hypertensive or have renal dysfunction and a history of prior stroke than those who received GPI ( Table 1) . Conversely, patients who were treated with pre-sheath or in-lab GPIs had a more ST-deviation at baseline, a shorter time from symptom onset to randomization and to PCI, more frequent TIMI 0/1 flow rates before PCI. They also had lower TIMI 3 flow rates post-intervention but greater ST-deviation resolution 
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Continued post-PCI when compared with those patients without GPI. Concomitant medications administered prior to randomization, in-hospital, or at discharge are listed in Table 1 . Aspirin and thienopyridine use, in general, was higher in GPI patients, whereas there was no difference in the rate of administration of unfractionated heparin. The use of low molecular weight heparin was lower in GPI-treated patients, especially in those treated with pre-sheath.
There was geographic variation both in the overall use and timing of GPI. Regional usage was as follows: North America, 84.6%; Western Europe, 75.7%; Eastern Europe, 36.5%; Australia/ New Zealand, 73.4%. Of all GPI patients, pre-sheath administration was highest in North America at 37.9% (Western Europe, 28.4%; Eastern Europe, 6.2%; Australia/New Zealand, 13.3%). In Table 2 and Figure 2 , the timing and specific GPI agents used are detailed. Abciximab was the most frequently administered agent in this trial (64.8%), followed by eptifibatide (28.7%) and tirofiban (6.5%). There was greater proportional pre-sheath initiation of the small-molecule GPIs. Figure 2 depicts all GPI patients distributed according to GPI timing relative to cardiac catheterization and PCI. Pre-sheath initiation of therapy occurred 37 (16 -66) min (median; 25th, 75th percentile) before sheath insertion and 56 (31-88) min before balloon inflation. Glycoprotein IIb/IIIa inhibitor was administered 16 min (10-27) after sheath insertion in in-lab GPI patients.
The observed 90-day clinical outcomes according to GPI administration are presented in Table 3 . Patients with pre-sheath use were associated with significantly less hazard (adjusted HR 0.68, 95% CI 0.48-0.95) after adjustment when compared with patients without GPI or in-lab GPI (Figure 3) . Both in-lab vs. no GPI use and pre-sheath vs. in-lab GPI use showed a trend for survival benefit. Similar to mortality, pre-sheath GPI was associated with a less hazard of 90-day death/CHF/shock when compared with no or in-lab use (adjusted HR 0.81, 95% CI 0.65 -1.00, P ¼ 0.054), and relative to in-lab GPI, pre-sheath administration was associated with a non-significant 14% relative decrease in the hazard of these events (adjusted HR 0.86, 95% CI 0.68-1.08, P ¼ 0.195). In-lab GPI, however, was significantly associated with lower hazard than in those with no GPI after adjustment for confounders (adjusted HR 0.77, 95% CI 0.64-0.92, P ¼ 0.005). In a subgroup analysis, a significant relationship between lower mortality with abciximab use and pre-sheath administration vs. no/in-lab users and in-lab users was observed (adjusted HR 0. Severe or moderate bleeding complications were infrequent and comparable between GPI-treated and non-treated or GPI presheath or in-lab use ( Table 3) . The in-hospital stroke rate was significantly lower in GPI-treated patients compared with those not (0.6 vs. 1.2%, P ¼ 0.02); among those with stroke, the aetiology (i.e. haemorrhagic, ischaemic, or unknown) was similar. The median time from randomization to stroke for non-GPI patients was 18.6 min (3.05-77.3) vs. GPI 31.4 (13.4-45.6, P ¼ 0.285). At 90 days, however, the difference in the stroke rate was attenuated. No differences in bleeding or stroke rates were evident for the different GPIs used.
Discussion
The main finding of the present investigation performed in a large cohort of patients with acute ST-elevation myocardial infarction referred for primary PCI is that early treatment with GPIs is associated with lower 90-day mortality and the combined centrally adjudicated endpoint of death, heart failure, or shock when compared with no or in-lab GPI use. Moreover, this occurred without a significant increase in moderate and/or severe bleeding complications. In addition, the relationship of better outcome with GPIs in our study appeared to be most evident with abciximab as opposed to the small-molecule GPIs.
Recent investigations have demonstrated that time-to-treatment is a crucial issue in primary angioplasty of acute ST-elevation myocardial infarction, with a significant impact on mortality. 4, 31, 32 Accordingly, it has been hypothesized that early administration of GPIs may induce earlier reperfusion, resulting in more successful PCI, reduced infarct size, and improved survival, particularly when long-distance transportation is required. 3, 7, 33 Several randomized trials have been conducted to investigate the benefits from early administration of GPIs in patients undergoing primary angioplasty. 8 -19,34,35 The largest experience derived from abciximab use has been shown in meta-analyses to either reduce mortality among patients undergoing primary angioplasty 6 or to increase the rate of aborted infarction. Figure 3 Adjusted hazard ratios (robust 95% CI) for 90-day clinical outcomes according to the glycoprotein IIb/IIIa inhibitor administration.
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A subanalysis of the Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up trial showed that early abciximab administration (in the emergency department or in the ambulance) also improved clinical outcome as compared to late administration. 22 The Early Glycoprotein IIb/IIIa inhibitors in Primary angioplasty cooperation 23 performed a meta-analysis to evaluate the benefits from early administration of GPIs in patients undergoing primary angioplasty, based on individual data of 1662 patients enrolled in 11 randomized trial 8 -10,12 The main finding of this meta-analysis was that facilitation with GPIs improved pre-procedural recanalization.
In the subanalysis limited to the abciximab trials, there was a significant mortality reduction for early vs. later use of abciximab. While significantly improved pre-procedural recanalization was the major benefit of early GPI use in the current study, there were also suggestions of improved myocardial reperfusion. Most notably, complete ST-segment resolution was significantly higher overall with pre-PCI GPI use and the relationship between this marker and mortality has been previously established. 36 The underlying mechanisms for these beneficial effects may be the diminished distal embolisation of platelet aggregates or inhibition of direct interaction of platelets with the reperfused endothelium by abciximab. 37, 38 Not all studies have demonstrated such clinical benefits from early GPI use. In a 2006 overview performed on pharmacological facilitation in primary angioplasty, no overall benefits in shortterm (30 days) mortality were observed with GPIs, 39 and their use was discouraged by the authors in daily clinical practice, outside of randomized trials. However, the 2006 report did not include several currently available trials and analysed only a restricted number of endpoints with limited duration of follow-up and no pre-specified subanalysis was performed according to the type of agent. Disappointing results have also been observed in the FINESSE trial. 24 This randomized prospective trial was prematurely stopped due to slow recruitment, with inclusion of up to 2400 STEMI patients. No advantages in terms of clinical outcome were observed at 3-month follow-up with pre-lab initiation of either combo-therapy (abciximab and half-dose reteplase) or abciximab, when compared with late peri-procedural abciximab administration, although higher patency rates in the first diagnostic angiogram were shown mainly with combination therapy. Differences in regional distribution and concomitant therapies may have contributed to these findings. The slow recruitment rate observed in the FINESSE trial may have also produced selection bias. Other important differences in FINESSE vs. the current study, potentially explaining the differences include; the smaller number of patients treated with GPI alone in FINESSE, the broader inclusion criteria in APEX, i.e. patients at risk to bleeding and a symptom onset to PCI in APEX which was about 55 min shorter in that in FINESSE, i.e. 200 vs. 255 min. As is the case with fibrinolytic therapy, pre-lab administration of GPIs may be more efficacious when primary PCI is performed at a relatively early stage of infarction, when more myocardium can be preserved. 33, 40 The excess bleeding observed in FINESSE patients pretreated with abciximab may have negatively influenced the clinical outcomes and was not evident in our study.
Recent registry data from Ortolani et al. 41 in Italy are well aligned with our report. These investigators studied 1123 STEMI patients undergoing primary PCI in an organized hub and spoke network. The 380 patients who received GPI agents 58 min earlier and prior to PCI had reduction in the composite outcome of 2-year death/MI in 1124 STEMI patients from 23 to 17% (HR 0.71, 95% CI 0.53-0.96, P ¼ 0.03) when compared with those who received in-lab GPI.
Limitations
Some limitations in our study deserve comment. Although we had a very comprehensive set of data, particularly relative to most registries and population-based cohorts, there may have been unmeasured confounding factors for which our adjusted analyses could not account. Although our data support prior reports of better efficacy with abciximab when compared with the small-molecule eptifibatide/tirofiban, these comparisons must be made with caution given the uncontrolled features of most trials including our own. Moreover, because we do not have exact dosing information, it is possible that the small molecular weight agents were relatively under dosed given that recent work with higher dosages shows more promising results. 36, 42 Although our retrospective analysis of a prospective randomized trial was not initially designed to test the efficacy of GPI, it stands as the largest trial thus far in acute STEMI patients referred for primary angioplasty with an about 70% use of GPIs of which 28% received the agent early and reflects a 'real-world' situation.
Conclusions
This analysis of a large contemporary patient cohort with acute STEMI undergoing PCI with early (pre-sheath), late (in-lab), or non-use of GPIs indicates that pharmacological pre-treatment of PCI appeared to be associated with significantly lower 90-day mortality as well as the combined clinical endpoint of death, shock, and heart failure. This supports earlier investigations, which favour an early use of GPIs in this clinical setting.
